GSK to buy rare cancer drug developer IDRx for up to £1bn
GSK can pay $1bn upfront to amass the Massachussetts-based firm IDRx is growing a remedy for gastrointestinal stromal tumours (GIST)By HARRY ...
Tag: IDRx
Stay ahead of the curve with Challengeric - your trusted source for comprehensive European news, including in-depth coverage of Cyprus. Explore the latest developments shaping the continent and beyond, with timely, accurate reporting and insightful analysis.